MedTrace Logo

Evaluation of the Safety and Efficacy of REBORN System for Lipolysis Treatment

NCT05507528 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2024-02-15

No results posted yet for this study

Summary

The Lightfective ReBorn System is intended for non-invasive lipolysis of the flanks in individuals with a Body Mass Index (BMI) of 30 or less. The device is intended to affect the appearance of visible fat bulges in the flanks.

Conditions

  • LIPOLYSIS

Interventions

DEVICE

reborn treatment

Fat reduction treatments with the ReBorn LED System visit - include the treatment procedure

Sponsors & Collaborators

  • Lightfective Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-30
Primary Completion
2023-11-11
Completion
2023-11-11
FDA Device
Yes

Countries

  • United States
  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05507528 on ClinicalTrials.gov